Experienced in Peripheral T-Cell Lymphoma

Diane Coso

Marseille, FR 
Experienced in Peripheral T-Cell Lymphoma
Marseille, FR 
OverviewLocationsClinical Research

Overview

Diane Coso practices in Marseille, France. Ms. Coso is rated as an Experienced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. Her top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Graft.

Her clinical research consists of co-authoring 44 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Female

Locations

Marseille, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
A Phase Ib/II Study of OBINUTUZUMAB Combined to LENALIDOMIDE for the Treatment of Follicular and Relapsed/Refractory Aggressive (DLBCL and MCL) B-cell Lymphoma
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Lenalidomide and GA101
Study Phase: Phase 1/Phase 2
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Randomized Phase III Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+
Enrollment Status: Completed
Publish Date: July 14, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

44 Total Publications

A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 03, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Coso's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile